Victoza improves blood-sugar levels in African-Americans, study finds

ORLANDO, Fla. African-Americans with Type 2 diabetes taking a Novo Nordisk drug showed improvements in blood sugar, according to a study presented Wednesday at a medical conference.

Novo Nordisk said that of the 187 African-American patients in the study of the drug Victoza (liraglutide [rDNA]), 78% of those taking the 1.8-mg dose and 55% of those taking the 1.2-mg dose once a day reached the American Diabetes Association’s blood sugar target of less than 7%, compared with 19% of those taking placebo. Results of the study were presented at the 2010 National Medical Association Annual Convention and Scientific Assembly in Orlando, Fla.

According to studies, African-Americans are 1.6 times more likely to have diabetes than non-Hispanic whites, and 25% of those between the ages of 65 and 74 years have the disease.

“This analysis confirms that Victoza is a safe and effective treatment for African-Americans with Type 2 diabetes and may be a good option for those patients struggling with blood sugar control,” study investigator and endocrinologist at New Jersey’s Robert Wood Johnson University Hospital Anthony Cannon said in a statement. “African-Americans are among the most affected by diabetes, so it’s important that we examine the safety and efficacy of diabetes treatment in this patient population.”

Recommended stories

Login or Register to post a comment.